AbbVie has launched its Produodopa therapy for Parkinson’s disease onto the market in the EU, becoming the first and only 24-hour levodopa-based subcutaneous ...

If you have advanced Parkinson’s disease (PD), you may hear about a treatment option called Vyalev (foscarbidopa/foslevodopa). It was approved by the FDA in 2024 ...

This pen truly is mightier than the sword. A team of researchers at UCLA has developed a high-tech diagnostic pen that can detect signs of Parkinson’s disease with over 96% accuracy, offering a ...

A County Durham man with Parkinson's disease has become one of the first patients in the country to receive a pioneering drug that "dramatically improves" the condition. Anthony Quinn, 49 and from ...

Onapgo is approved for adult Parkinson’s patients experiencing motor fluctuations. Credit: Inside Creative House via Getty Images. · Pharmaceutical Technology · Inside Creative House via Getty Images.

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The ...

Advanced Parkinson's disease is the later stage of PD, characterized by more severe motor and non-motor symptoms. As the disease progresses, patients experience significant challenges in managing ...

Centogene NV and ROPAD consortium publish data from a landmark study identifying genetic variants that may respond to innovative cell and gene therapies. Over the past decade, researchers have ...

BENGALURU: Parkinson’s disease (PD) has no cure, and the symptoms get worse as the disease progresses with the patient age. In the most advanced stage of PD, called end-stage or stage 5, patients may ...

Vyalev, also known as Produodopa, has been approved in 35 countries, with more than 4200 patients having started treatment. FDA has approved the AbbVie treatment Vyalev (foscarbidopa and foslevodopa) ...

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The ...